ID   FRTK-1
AC   CVCL_4W35
DR   Wikidata; Q54835178
RX   PubMed=16820901;
CC   Population: Japanese.
CC   Doubling time: ~24 hours (PubMed=16820901).
CC   Sequence variation: Mutation; HGNC; HGNC:11103; SMARCB1; Simple; p.Glu300Ter (c.898G>T); Zygosity=Unspecified (PubMed=16820901).
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
DI   NCIt; C8715; Rhabdoid tumor of the kidney
DI   ORDO; Orphanet_69077; Rhabdoid tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   1Y6M
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 19-12-24; Version: 10
//
RX   PubMed=16820901; DOI=10.3892/or.16.2.265;
RA   Hakozaki M., Hojo H., Sato M., Kaneko Y., Watanabe N., Kikuchi S.,
RA   Abe M.;
RT   "Establishment and characterization of a new cell line, FRTK-1,
RT   derived from human malignant rhabdoid tumor of the kidney, with
RT   overexpression of epidermal growth factor receptor and
RT   cyclooxygenase-2.";
RL   Oncol. Rep. 16:265-271(2006).
//